enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

ENGN Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

enGene Holdings Inc.NASDAQ: ENGN

Short-term Debt · Q2 FY2026 · quarter ended Apr 2026

Short-term debt falls 42.8% from a year ago

Short-term debt stood at $2.29M at the end of Q2 FY2026, down 42.8% from a year earlier and down 8.7% from the prior quarter. Over 3 fiscal years it compounded at +99.3% a year.

Context

  • Short-term debt amounted to 0.7% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
  • Short-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term debt keeps falling in the next quarterly balance sheet after a -42.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterApr 2026
$2.29M-8.7% QoQ
Last fiscal yearOct 2025
$10.02M+792.7% YoY
Year agoApr 2025
$4M-42.8% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.8%——
1 year+792.7%——
3-year CAGR+99.3%——
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
10.02M USD
Year-over-year change
+792.7%
4-year CAGR
+75.8%

Short-term Debt vs competitors

How ENGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -42.8% is the lowest of 4, against a peer median of +92.3%.
  • Short-term debt amounts to 0.7% of total assets for ENGN, versus a peer median of 0.0%.
ENGN Competitors
Short-term Debt for ENGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026$15.16M USD+200.8%+54.0%5.2%
DBVTDBV Technologies S.A.Mar 2026$11.2M USD+92.3%+143.2%4.2%
ENGNenGene Holdings Inc.Apr 2026$2.29M USD-42.8%+99.3%0.7%
ANROAlto Neuroscience, Inc.Mar 2026$2.14M USD—+27.4%0.8%
LRMRLarimar Therapeutics, Inc.Mar 2026$1.06M USD-3.5%—0.5%
SLNSilence Therapeutics plcMar 2026$0 USD——0.0%
ANNXAnnexon, Inc.Mar 2026$0 USD——0.0%
ALTAltimmune, Inc.Mar 2026$0 USD——0.0%
AMRNAmarin Corporation plcMar 2026$0 USD——0.0%
ACIUAC Immune S.A.Mar 2026CHF 0 CHF——0.0%
KRROKorro Bio, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding ENGN) —+92.3%+54.0%0.0%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Cash & Equivalents1.07M314.15K81.52M173M50.15M
Short-term Investments0076K65.4M143.66M
Net Receivables002.34M1.03M2.23M
Inventory00000
Other Current Assets001.5M7.93M5.35M
Total Current Assets1.57M511.8K85.44M247.36M201.39M
Property, Plant & Equipment (Net)00589K2.91M10.19M
Goodwill00000
Intangible Assets00000
Long-term Investments129.67M131.53M70K59.53M8.52M
Tax Assets00000
Other Non-current Assets209.05K939K860K1.37M1.36M
Total Non-current Assets129.88M131.53M1.52M63.81M20.08M
Total Assets131.45M132.04M86.96M311.17M221.47M
Account Payables001.16M1.41M6.69M
Short-term Debt1.05M1.27M562K1.12M10.02M
Tax Payables022K39K00
Deferred Revenue00000
Other Current Liabilities327.45K893.51K2.69M8.65M11.2M
Total Current Liabilities327.45K893.51K5.26M14.66M31.98M
Long-term Debt009.22M22.47M15.32M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)3.73M0000
Other Non-current Liabilities03.73M000
Total Non-current Liabilities3.73M3.73M9.22M23.9M21.78M
Total Liabilities4.05M4.62M14.47M38.56M53.76M
Common Stock129.67M131.53M259.37M509.81M513.28M
Retained Earnings(2.28M)(4.11M)(199.59M)(254.73M)(372.03M)
Accumulated OCI00(1.02M)(1.42M)(888K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity127.39M127.42M72.49M272.61M167.71M
Total Debt4.16M32.11M9.78M25.02M31.8M
Net Debt(1.07M)(314.15K)(71.74M)(147.98M)(18.36M)

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.